Prokarium closes USD21m Series B financing round
Prokarium, a privately-held biotechnology company developing novel immunotherapies and vaccines based on its engineered microbial platform, has closed a USD21 million Series B investment round led by Korea Investment Partners (KIP). In addition to KIP, the UK government’s Future Fund (FF), Flerie Invest and Riyadh Valley Company (RVC) also participated in